During a press conference at the 2013 ASH Annual Meeting, Dr Alan Gamis presents results from a recent randomised phase III trial.

For children diagnosed with cancer, their post-treatment relapse rate is one of the major indicators of their potential for long-term survival. This research program evaluated whether adding the monoclonal antibody gemtuzumab (GO) to standard chemotherapy might improve event-free survival without causing excessive toxicity and mortality in children with acute myeloid leukaemia (AML).